Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Breast Cancer: Clinical Trial and Translational Research
share announcement

Breast Cancer: Clinical Trial and Translational Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (23 October 2023) | Viewed by 10258

Special Issue Editors

Dr. Hirokazu Tanino

E-Mail Website
Guest Editor
Division of Breast Surgery, Department of Surgery, Wakayama Medical University, Wakayama, Japan
Interests: breast cancer; triple negative breast cancer; chemotherapy; miRNA; exosome; xenograft
Dr. Masayuki Nagahashi

E-Mail Website
Guest Editor
Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University, Nishinomiya, Japan
Interests: breast cancer
Dr. Akari Murakami

E-Mail Website
Co-Guest Editor
Department of Breast Center, Ehime University Hospital, Ehime 791-0204, Japan
Interests: breast cancer

Special Issue Information

Dear Colleagues,

Researchers discover the seeds of new medical technologies and treatments in basic research. Translational research refers to research conducted with the aim of commercializing these seeds of medicine into new medical technologies and drugs that can be used in actual medical institutions. Therefore, it covers a wide range of areas from preclinical to clinical development, including not only therapeutic drugs but also technologies for detecting breast cancer, assisting surgery, and so on.

In this SPECIAL EDITION, we hope that you will publish data that are in the process of proving excellent technology, in a state that is about to go from the lab to the clinic. We look forward to receiving submissions from many of you.

Dr. Hirokazu Tanino
Dr. Masayuki Nagahashi
Dr. Akari Murakami
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • translational research
  • clinical trial
  • new technology
  • early detection
  • new drug
  • targeting

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

15 pages, 55986 KiB  
Article
Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma
by George Sflomos, Nora Schaumann, Matthias Christgen, Henriette Christgen, Stephan Bartels, Hans Kreipe, Laura Battista and Cathrin Brisken
Cancers 2023, 15(13), 3299; https://doi.org/10.3390/cancers15133299 - 22 Jun 2023
Cited by 1 | Viewed by 2617
Abstract
Invasive lobular carcinoma (ILC) is a common breast cancer subtype that is often diagnosed at advanced stages and causes significant morbidity. Late-onset secondary tumor recurrence affects up to 30% of ILC patients, posing a therapeutic challenge if resistance to systemic therapy develops. Nonetheless, [...] Read more.
Invasive lobular carcinoma (ILC) is a common breast cancer subtype that is often diagnosed at advanced stages and causes significant morbidity. Late-onset secondary tumor recurrence affects up to 30% of ILC patients, posing a therapeutic challenge if resistance to systemic therapy develops. Nonetheless, there is a lack of preclinical models for ILC, and the current models do not accurately reproduce the complete range of the disease. We created clinically relevant metastatic xenografts to address this gap by grafting the triple-negative IPH-926 cell line into mouse milk ducts. The resulting intraductal xenografts accurately recapitulate lobular carcinoma in situ (LCIS), invasive lobular carcinoma, and metastatic ILC in relevant organs. Using a panel of 15 clinical markers, we characterized the intratumoral heterogeneity of primary and metastatic lesions. Interestingly, intraductal IPH-926 xenografts express low but actionable HER2 and are not dependent on supplementation with the ovarian hormone estradiol for their growth. This model provides a valuable tool to test the efficiency of potential new ILC therapeutics, and it may help detect vulnerabilities within ILC that can be exploited for therapeutic targeting. Full article
(This article belongs to the Special Issue Breast Cancer: Clinical Trial and Translational Research)
►▼ Show Figures

Figure 1

14 pages, 634 KiB  
Article
Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial
by Nhu Hanh To, Isabelle Gabelle-Flandin, Thi My Hanh Luong, Gokoulakrichenane Loganadane, Nabila Ouidir, Chahrazed Boukhobza, Noémie Grellier, Camille Verry, Allan Thiolat, José L. Cohen, Nina Radosevic-Robin and Yazid Belkacemi
Cancers 2023, 15(7), 2030; https://doi.org/10.3390/cancers15072030 - 29 Mar 2023
Viewed by 1433
Abstract
Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate immunity-related indicators of response to neoadjuvant chemoradiation therapy (NACRT) in BC for better [...] Read more.
Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate immunity-related indicators of response to neoadjuvant chemoradiation therapy (NACRT) in BC for better treatment personalization. Patients and Methods: We analyzed data of the first 42 patients included in the randomized phase 2 Neo-APBI-01 trial comparing standard neoadjuvant chemotherapy (NACT) and NACRT regimen in locally advanced triple-negative (TN) and luminal B (LB) subtype BC. Clinicopathological parameters, blood counts and the derived parameters, total tumor-infiltrating lymphocytes (TILs) and their subpopulation, as well as TP53 mutation status, were assessed as predictors of response. Results: Twenty-one patients were equally assigned to each group. The pathologic complete response (pCR) was 33% and 38% in the NACT and NACRT groups, respectively, with a dose-response effect. Only one LB tumor reached pCR after NACRT. Numerous parameters associated with response were identified, which differed according to the assigned treatment. In the NACRT group, baseline hemoglobin of ≥13 g/dL and body mass index of <26 were strongly associated with pCR. Higher baseline neutrophils-to-lymphocytes ratio, total TILs, and T-effector cell counts were favorable for pCR. Conclusion: This preliminary analysis identified LB and low-TIL tumors as poor responders to the NACRT protocol, which delivered RT after several cycles of chemotherapy. These findings will allow for amending the selection of patients for the trial and help better design future trials of NACRT in BC. Full article
(This article belongs to the Special Issue Breast Cancer: Clinical Trial and Translational Research)
►▼ Show Figures

Figure 1

12 pages, 569 KiB  
Article
Trajectories of Quality of Life among an International Sample of Women during the First Year after the Diagnosis of Early Breast Cancer: A Latent Growth Curve Analysis
by Ruth Pat-Horenczyk, Lauren Kelada, Eleni Kolokotroni, Georgios Stamatakos, Rawan Dahabre, Gabriella Bentley, Shlomit Perry, Evangelos C. Karademas, Panagiotis Simos, Paula Poikonen-Saksela, Ketti Mazzocco, Berta Sousa, Albino J. Oliveira-Maia and Ilan Roziner
Cancers 2023, 15(7), 1961; https://doi.org/10.3390/cancers15071961 - 24 Mar 2023
Cited by 1 | Viewed by 990
Abstract
The current study aimed to track the trajectory of quality of life (QoL) among subgroups of women with breast cancer in the first 12 months post-diagnosis. We also aimed to assess the number and portion of women classified into each distinct trajectory and [...] Read more.
The current study aimed to track the trajectory of quality of life (QoL) among subgroups of women with breast cancer in the first 12 months post-diagnosis. We also aimed to assess the number and portion of women classified into each distinct trajectory and the sociodemographic, clinical, and psychosocial factors associated with these trajectories. The international sample included 699 participants who were recruited soon after being diagnosed with breast cancer as part of the BOUNCE Project. QoL was assessed at baseline and after 3, 6, 9, and 12 months, and we used Latent Class Growth Analysis to identify trajectory subgroups. Sociodemographic, clinical, and psychosocial factors at baseline were used to predict latent class membership. Four distinct QoL trajectories were identified in the first 12 months after a breast cancer diagnosis: medium and stable (26% of participants); medium and improving (47%); high and improving (18%); and low and stable (9%). Thus, most women experienced improvements in QoL during the first year post-diagnosis. However, approximately one-third of women experienced consistently low-to-medium QoL. Cancer stage was the only variable which was related to the QoL trajectory in the multivariate analysis. Early interventions which specifically target women who are at risk of ongoing low QoL are needed. Full article
(This article belongs to the Special Issue Breast Cancer: Clinical Trial and Translational Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

23 pages, 574 KiB  
Review
Systemic Therapies for HER2-Positive Advanced Breast Cancer
by Vasileios Angelis and Alicia F. C. Okines
Cancers 2024, 16(1), 23; https://doi.org/10.3390/cancers16010023 - 20 Dec 2023
Viewed by 1469
Abstract
Despite recent advances, HER2-positive advanced breast cancer (ABC) remains a largely incurable disease, with resistance to conventional anti-HER2 drugs ultimately unavoidable for all but a small minority of patients who achieve an enduring remission and possibly cure. Over the past two decades, significant [...] Read more.
Despite recent advances, HER2-positive advanced breast cancer (ABC) remains a largely incurable disease, with resistance to conventional anti-HER2 drugs ultimately unavoidable for all but a small minority of patients who achieve an enduring remission and possibly cure. Over the past two decades, significant advances in our understanding of the underlying molecular mechanisms of HER2-driven oncogenesis have translated into pharmaceutical advances, with the developing of increasingly sophisticated therapies directed against HER2. These include novel, more potent selective HER2 tyrosine kinase inhibitors (TKIs); new anti-HER2 antibody-drug conjugates; and dual epitope targeting antibodies, with more advanced pharmacological properties and higher affinity. With the introduction of adjuvant T-DM1 for incomplete responders to neoadjuvant therapy, fewer patients are relapsing, but for those who do relapse, disease that may be resistant to standard first- and second-line therapies requires new approaches. Furthermore, the risk of CNS relapse has not been abrogated by current (neo)adjuvant strategies; therefore, current research efforts are being directed towards this challenging site of metastatic disease. In this article, we review the currently available clinical data informing the effective management of HER2-positive breast cancer beyond standard first-line therapy with pertuzumab, trastuzumab, and taxanes, and the management of relapse in patients who have already been exposed to both these agents and T-DM1 for early breast cancer (EBC). We additionally discuss novel anti-HER2 targeted agents and combinations in clinical trials, which may be integrated into standard treatment paradigms in the future. Full article
(This article belongs to the Special Issue Breast Cancer: Clinical Trial and Translational Research)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

21 pages, 530 KiB  
Systematic Review
Guidelines for Cancer Treatment during Pregnancy: Ethics-Related Content Evolution and Implications for Clinicians
by Alma Linkeviciute, Rita Canario, Fedro Alessandro Peccatori and Kris Dierickx
Cancers 2022, 14(17), 4325; https://doi.org/10.3390/cancers14174325 - 03 Sep 2022
Cited by 8 | Viewed by 3129
Abstract
(1) Background: Current scientific evidence suggests that most cancers, including breast cancer, can be treated during pregnancy without compromising maternal and fetal outcomes. This, however, raises questions regarding the ethical implications of clinical care. (2) Methods: Using a systematic literature search, 32 clinical [...] Read more.
(1) Background: Current scientific evidence suggests that most cancers, including breast cancer, can be treated during pregnancy without compromising maternal and fetal outcomes. This, however, raises questions regarding the ethical implications of clinical care. (2) Methods: Using a systematic literature search, 32 clinical practice guidelines for cancer treatment during pregnancy published between 2002 and 2021 were selected for analysis and 25 of them mentioned or made references to medical ethics when offering clinical management guidance for clinicians. (3) Results: Four bioethical themes were identified: respect for patient’s autonomy, balanced approach to maternal and fetal beneficence, protection of the vulnerable and justice in resource allocation. Most guidelines recommended informing the pregnant patient about available evidence-based treatment options, offering counselling and support in the process of decision making. The relational aspect of a pregnant patient’s autonomy was also recognized and endorsed in a significant number of available guidelines. (4) Conclusions: Recognition and support of a patient’s autonomy and its relational aspects should remain an integral part of future clinical practice guidelines. Nevertheless, a more structured approach is needed when addressing existing and potential ethical issues in clinical practice guidelines for cancer treatment during pregnancy. Full article
(This article belongs to the Special Issue Breast Cancer: Clinical Trial and Translational Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop